A randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis.

Kyunguk JeongMincheol KimSe Ah JeonYoung-Hoo KimSooyoung Lee

Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020)

In children with moderate AD, oral administration of RHT3201 showed the therapeutic effect on AD, the effects in part correlated with decrement of ECP and IL-31, and the effect was more remarkable in subgroup analysis.

Keyphrases

atopic dermatitis
young adults
high intensity
randomized controlled trial
clinical trial
phase iii
open label
double blind
lactic acid
data analysis
placebo controlled